Physician profile
Daniel Bentall
NPI 1720856008
$3,072.10
in general payments reported to CMS, 2019-2025
14 companies · $3,072 in 2025
The $3,072 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $3,072.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,310 · Travel and Lodging: $762.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,310.45 |
| Travel and Lodging | $761.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,428.94 | 2025 | Wavewriter Alpha Prime 16, General - Pain Management |
| Janssen Pharmaceuticals, INC | $435.83 | 2025 | Spravato |
| Abbvie INC. | $291.69 | 2025 | |
| Pfizer INC. | $268.51 | 2025 | |
| Valinor Pharma, LLC | $183.40 | 2025 | Movantik |
| Collegium Pharmaceutical, INC. | $103.35 | 2025 | Belbuca, Xtampza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $96.75 | 2025 | Relistor, Trulance |
| Lundbeck LLC | $67.27 | 2025 | Vyepti |
| Averitas Pharma INC. | $58.30 | 2025 | Qutenza |
| Vertex Pharmaceuticals Incorporated | $37.14 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $35.60 | 2025 | Austedo Xr |
| Merz Pharmaceuticals, LLC | $25.09 | 2025 | Xeomin |
| Spr Therapeutics, INC | $22.57 | 2025 | Sprint Pns System |
| Indivior INC. | $17.66 | 2025 | Sublocade |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Bentall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.